wseas-12101-20260928105317-2a5430 20260928105317161 wseas/wseas wseas.group@gmail.com WSEAS WSEAS Transactions on Biology and Biomedicine 1109-9518 2224-2902 10 06 2025 10 06 2025 23 Shorena Gabaidze Faculty of Natural Sciences and Health Care, Batumi Shota Rustaveli State University, 32/35 Rustaveli/Ninoshvili St, Batumi 6010, Adjara, GEORGIA Marina Nagervadze Faculty of Natural Sciences and Health Care, Batumi Shota Rustaveli State University, 32/35 Rustaveli/Ninoshvili St, Batumi 6010, Adjara, GEORGIA Leila Akhvlediani Faculty of Natural Sciences and Health Care, Batumi Shota Rustaveli State University, 32/35 Rustaveli/Ninoshvili St, Batumi 6010, Adjara, GEORGIA Nato Gorgadze Iris Borchashvili Health Center Medina, 237 Fridon Khalvashi St, Batumi 6010, Adjara, GEORGIA Tamar Bakhtadze M. Iashvili Batumi Maternal and Child Central Hospital, 64 Airport Highway, Batumi 6010, Adjara GEORGIA Rusudan Khukhunaishvili Faculty of Natural Sciences and Health Care, Batumi Shota Rustaveli State University, 32/35 Rustaveli/Ninoshvili St, Batumi 6010, Adjara, GEORGIA Jumber Ungiadze Iris Borchashvili Health Center Medina, 237 Fridon Khalvashi St, Batumi 6010, Adjara, GEORGIA Hemolytic disease of the fetus and newborn (HDFN) is a blood disorder in which red blood cells are destroyed faster, leading to anemia. Our study focused on immune-mediated HDFN. The study included 86 newborns with HDFN. Samples were provided to two clinics in Georgia. Coombs tests were performed to confirm the presence of HDFN. Monoclonal antibodies were used to determine ABO and Rh blood group antigens. The genetic analysis was performed using the SNP rs8176719. ABO-HDFN was the majority, followed by Rh-HDFN (χ2 = 6.44, p = 0.04). the majority newborns with ABO-HDFN have A(II), Rh+ blood group (χ2 =141.16, p 09 28 2026 09 28 2026 300 28 https://creativecommons.org/licenses/by/4.0/ 10.37394/23208.2026.23.28 https://wseas.com/journals/articles.php?id=12101 H. M. Yaish, R. D. Christensen, and R. S. Lemons, “Neonatal nonimmune hemolytic anemia,” Curr. Opin. Pediatr., vol. 29, no. 1, pp. 12–19, Feb. 2017, doi: 10.1097/MOP.0000000000000440. J. Castillo, T. E. Ness, and P. S. Mehta, “Infantile Pyknocytosis: An Uncommon Cause of Newborn Hemolytic Anemia,” J. Pediatr. Hematol. Oncol., vol. 42, no. 4, pp. e251–e253, May 2020, doi: 10.1097/MPH.0000000000001461. A. Karanam and P. Bandiya, “Hemolytic Disease of Newborn: Beyond Rh-D and ABO Incompatibility,” Indian Pediatr., vol. 58, no. 8, pp. 794–795, Aug. 2021. P. Komvilaisak et al., “Many faces of non‑ deletional α‑ thalassaemia variants in neonate and early childhood,” Ann. Hematol., vol. 105, no. 3, p. 80, Feb. 2026, doi: 10.1007/s00277-026-06856-x. D. P. De Winter et al., “Infant Immunity after Maternal Nipocalimab in Severe Hemolytic Disease of the Fetus and Newborn,” NEJM Evid., vol. 5, no. 2, Jan. 2026, doi: 10.1056/EVIDoa2500097. D. P. Blackall and M. W. Tomlinson, “Confusing Blood Group Antibodies in Obstetrics: Focus on the Risk of Hemolytic Disease of the Fetus and Newborn,” Am. J. Perinatol., vol. 43, no. 02, pp. 266–271, Jan. 2026, doi: 10.1055/a-2622-2841. S. M. Ares, L. M. M. Nardozza, E. Araujo, and E. F. M. Santana, “Non-RhD alloimmunization in pregnancy: an updated review,” Rev. Bras. Ginecol. E Obstetrícia RBGO Gynecol. Obstet., vol. 46, p. e-rbgo22, Mar. 2024, doi: 10.61622/rbgo/2024AO22. B. Singh, R. Chaudhary, and R. Katharia, “Title: Effect of multiple maternal red cell alloantibodies on the occurrence and severity of Hemolytic Disease of the Fetus and Newborn,” Transfus. Apher. Sci., vol. 60, no. 1, p. 102958, Feb. 2021, doi: 10.1016/j.transci.2020.102958. D. Sachan, V. Thiyagarajan, and D. K. G, “A case of assisted reproductive technology–induced maternal alloimmunization: an emerging sensitizing factor to consider?,” Immunohematology, vol. 40, no. 4, pp. 149–152, Dec. 2024, doi: 10.2478/immunohematology-2024-020. E. Hrastar, I. Bricl, T. Premru-Sršen, J. Gubenšek, L. Kornhauser Cerar, and P. Pečlin, “Successful management of severe hemolytic disease of the fetus and newborn (HDFN) due to anti-Kell,” J. Perinat. Med., vol. 54, no. 1, pp. 100–107, Jan. 2026, doi: 10.1515/jpm-2025-0347. S. Lawicki, R. B. Covin, and A. A. Powers, “The Kidd (JK) Blood Group System,” Transfus. Med. Rev., vol. 31, no. 3, pp. 165–172, Jul. 2017, doi: 10.1016/j.tmrv.2016.10.003. S. K. Iyyapan, H. H. Annadurai, G. P. Thangavel, and H. Natesan, “Hemolytic disease of fetus and newborn due to maternal AlloAnti-S antibody,” Asian J. Transfus. Sci., vol. 18, no. 2, pp. 333–335, Jul. 2024, doi: 10.4103/ajts.ajts_154_22. M. Kaplan et al., “Failure to Predict Hemolysis and Hyperbilirubinemia by IgG Subclass in Blood Group A or B Infants Born to Group O Mothers,” Pediatrics, vol. 123, no. 1, pp. e132–e137, Jan. 2009, doi: 10.1542/peds.2008-2617. J. Liu, X. Liu, and W. Fang, “Recent advances in chemoenzymatic synthesis of human ABO blood group antigens,” Biotechnol. Adv., vol. 82, p. 108599, Sep. 2025, doi: 10.1016/j.biotechadv.2025.108599. T. I. Withanawasam and N. Sainudeen, “Prevalence and clinical implications of unexpected red blood cell antibodies in a tertiary care hospital in Sri Lanka,” Immunohematology, vol. 41, no. 1, pp. 4–10, Mar. 2025, doi: 10.2478/immunohematology-2025-003. A. Desalew et al., “RhD alloimmunization in pregnancy and hemolytic disease of the fetus and newborn in Africa: A systematic review and meta-analysis,” Best Pract. Res. Clin. Obstet. Gynaecol., vol. 104, p. 102700, Feb. 2026, doi: 10.1016/j.bpobgyn.2025.102700. A. A. Ayenew, “Prevalence of rhesus D-negative blood type and the challenges of rhesus D immunoprophylaxis among obstetric population in Ethiopia: a systematic review and meta-analysis,” Matern. Health Neonatol. Perinatol., vol. 7, no. 1, p. 8, Dec. 2021, doi: 10.1186/s40748-021-00129-3. R. P. Sugrue et al., “Maternal red blood cell alloimmunization prevalence in the United States,” Blood Adv., vol. 8, no. 16, pp. 4311–4319, Aug. 2024, doi: 10.1182/bloodadvances.2023012241. S. Gabaidze et al., “ABO and Rh Blood Group Antigens and Natural Anti-A and ANTI-B Antibodies in the Neonates,” WSEAS Trans. Biol. Biomed., vol. 20, pp. 186–196, Oct. 2023, doi: 10.37394/23208.2023.20.19. H. Li et al., “Population-specific ABO haplotypes reveal distinct venous thromboembolism risk in East Asians: insights from a large-scale genetic study,” Lancet Reg. Health - West. Pac., vol. 66, p. 101781, Jan. 2026, doi: 10.1016/j.lanwpc.2025.101781. T. Kvasnicka et al., “The Prevalence of the Thrombotic SNPs rs6025, rs1799963, rs2066865, rs2289252 and rs8176719 in Patients with Venous Thromboembolism in the Czech Population,” Clin. Appl. Thromb., vol. 31, p. 10760296251324202, Oct. 2025, doi: 10.1177/10760296251324202. S. F. Natae et al., “The Higher Prevalence of Venous Thromboembolism in the Hungarian Roma Population Could Be Due to Elevated Genetic Risk and Stronger Gene-Environmental Interactions,” Front. Cardiovasc. Med., vol. 8, p. 647416, Oct. 2021, doi: 10.3389/fcvm.2021.647416. E. M. Hald, M.-L. Løchen, E. B. Mathiesen, K. Hveem, S. K. Brækkan, and J.-B. Hansen, “Joint effects of atrial fibrillation and prothrombotic genotypes on the risk of ischemic stroke,” J. Thromb. Haemost., vol. 23, no. 4, pp. 1401–1406, Apr. 2025, doi: 10.1016/j.jtha.2024.12.022. J. H. Karnes et al., “ABO O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia,” Blood, vol. 140, no. 3, pp. 274–284, Jul. 2022, doi: 10.1182/blood.2021014240. S. Lehrer and P. H. Rheinstein, “ABO blood groups, COVID-19 infection and mortality,” Blood Cells. Mol. Dis., vol. 89, p. 102571, Jul. 2021, doi: 10.1016/j.bcmd.2021.102571. “https://www.socscistatistics.com/tests/(Accessed Date: January 1, 2026).” “https://Www.Snpedia.Com/Index.Php/Rs8176719, (Accessed Date: August, 11, 2026).” Accessed: January 1, 2026. [Online]. Available: https://www.snpedia.com/index.php/rs8176719. S. Sekhar Das, A. Roy, S. Mukherjee, and S. Chowdhury, “Estimation of ABO hemolytic disease of the fetus and newborn through gene frequency study and immunohematological characterization of the disease,” Transfus. Apher. Sci., vol. 64, no. 3, p. 104120, Jun. 2025, doi: 10.1016/j.transci.2025.104120. R. Wang, Y. Li, Y. Tong, and N. Su, “Hemolytic Disease of the Fetus and Newborn Caused by Anti-Group A IgG From a Group B Mother,” J. Pediatr. Hematol. Oncol., vol. 43, no. 6, pp. e785–e787, Aug. 2021, doi: 10.1097/MPH.0000000000001948. N. Aashiqeen et al., “Comparison of anti-A and anti-B isoagglutinin titers by conventional tube and column agglutination technique in O Rh-D positive mothers and their impact on neonatal outcomes,” Transfus. Apher. Sci., vol. 64, no. 4, p. 104170, Aug. 2025, doi: 10.1016/j.transci.2025.104170. G. R. Krog, H. Lorenzen, F. B. Clausen, A. T. Hansen, M. L. Donneborg, and M. H. Dziegiel, “ABO haemolytic disease of the newborn: Improved prediction by novel integration of causative and protective factors in newborn and mother,” Vox Sang., vol. 117, no. 3, pp. 415–423, Mar. 2022, doi: 10.1111/vox.13195. C. Dilbaz Akyuz, S. Arayici, B. Akcan Paksoy, and B. Akyuz, “Assessing blood carboxyhemoglobin levels as an early predictor of phototherapy in ABO incompatible newborns,” J. Neonatal-Perinat. Med., vol. 19, no. 5, pp. 500–507, Sep. 2026, doi: 10.1177/19345798261424781. A. M. Schwalb, J. J. Federspiel, S. Dotters-Katz, J. A. Kuller, and R. P. Sugrue, “Rhesus D Prophylaxis: When and Why We Give Rhesus D Immunoglobulin,” Obstet. Gynecol. Surv., vol. 80, no. 5, pp. 315–324, May 2025, doi: 10.1097/OGX.0000000000001391. R. M. Jacob Vatakencherry, S. John, V. Shenoy, and L. Saraswathy, “Prevalence of alloantibodies among antenatal women attending a teaching hospital in central Kerala,” J. Fam. Med. Prim. Care, vol. 14, no. 8, pp. 3538–3541, Aug. 2025, doi: 10.4103/jfmpc.jfmpc_407_25. K. Gemzell‐ Danielsson et al., “Rhesus testing and anti‐ D prophylaxis in RhD‐ negative women undergoing first‐ trimester abortion—Systematic Review and Opinion,” Int. J. Gynecol. Obstet., vol. 172, no. 2, pp. 759–771, Feb. 2026, doi: 10.1002/ijgo.70404. M. Prabhu, J. M. Louis, and J. A. Kuller, “Society for Maternal-Fetal Medicine Statement: RhD immune globulin after spontaneous or induced abortion at less than 12 weeks of gestation,” Am. J. Obstet. Gynecol., vol. 230, no. 5, pp. B2–B5, May 2024, doi: 10.1016/j.ajog.2024.02.288. A. Sulaiman and M. Abdullahi, “Knowledge and Attitude of Pregnant Women on ABO and Rhesus Blood Grouping Towards Preventing Neonatal Hemolytic Disease at Rasheed Shekoni Federal University Teaching Hospital, Dutse, Jigawa State, Nigeria,” Niger. Med. J., pp. 1406-1422 Pages, Nov. 2025, doi: 10.71480/NMJ.V66I4.843. D. Davad, H. D. Majithiya, and J. Nagda, “Alloimmunization in a Rhesus (Rh) D-Negative Pregnant Woman With an Uncommon Rh Phenotype: A Case Report,” Cureus, Jun. 2025, doi: 10.7759/cureus.86861. S. Gabaidze, M. Nagervadze, L. Akhvlediani, T. Bakhtadze, N. Mikadze, and J. Ungiadze, “Postnatal Development of Blood Group Antigens and Antibodies in the First Year of Life,” WSEAS Trans. Biol. Biomed., vol. 22, pp. 82–93, Dec. 2024, doi: 10.37394/23208.2025.22.10. I. Tsintsadze et al., “Specific Combinations of Erythrocyte Group Antigens in Blood Donors,” Indian J. Hematol. Blood Transfus., vol. 36, no. 2, pp. 356–360, Apr. 2020, doi: 10.1007/s12288-019-01197-4. J. C. Yui and R. A. Brodsky, “Updates in the Management of Warm Autoimmune Hemolytic Anemia,” Hematol. Oncol. Clin. North Am., vol. 36, no. 2, pp. 325–339, Apr. 2022, doi: 10.1016/j.hoc.2021.11.005. K. Lange et al., “Early exposure, enduring consequences: How do I manage Rh immunoglobulin prophylaxis after Rh‐ mismatched transfusions in children?,” Transfusion (Paris), p. trf.70094, Feb. 2026, doi: 10.1111/trf.70094. J. S. Luken, A. Bouman, C. C. Folman, M. De Haas, and E. Van Den Akker‐ van Marle, “Cost‐ effectiveness of CEK ‐ preventive matched transfusion strategies for female transfusion recipients to prevent haemolytic disease of the foetus and newborn in the Dutch healthcare setting,” Vox Sang., p. vox.70212, Feb. 2026, doi: 10.1111/vox.70212. D. P. De Winter et al., “Antenatal risk estimation for exchange transfusions in neonates with hemolytic disease of the fetus and newborn in a changing treatment landscape: A multicenter, retrospective cohort study,” Transfusion (Paris), vol. 66, no. 2, pp. 296–305, Feb. 2026, doi: 10.1111/trf.70056. M. R. Grace, B. Goodhue, and N. L. Vora, “Rho(D) immune globulin shortage and fetal Rh(D) screening with cell-free DNA,” Curr. Opin. Obstet. Gynecol., vol. 37, no. 2, pp. 55–59, Apr. 2025, doi: 10.1097/GCO.0000000000001011. K. J. Moise et al., “A Clinical Practice Guideline for the Management of Pregnancy Alloimmunized to Red Blood Cell Antigens,” JAMA Netw. Open, vol. 8, no. 11, p. e2544649, Nov. 2025, doi: 10.1001/jamanetworkopen.2025.44649. D.-D. Jiang, J.-W. Li, and X.-C. Zhang, “Dual-biomarker strategy for prenatal prediction of ABO hemolytic disease: Maternal sVE-cadherin and anti-A/B IgG titer,” Medicine (Baltimore), vol. 105, no. 2, p. e47146, Jan. 2026, doi: 10.1097/MD.0000000000047146. W. Tang, L. Zhu, L. Shi, and B. Gu, “P-Selectin, Vascular Endothelial Cadherin, and Vascular Cell Adhesion Molecule‐ 1 as Novel Biomarkers for ABO Hemolytic Disease of the Fetus and Newborn,” Anal. Cell. Pathol., vol. 2025, no. 1, p. 9411137, Jan. 2025, doi: 10.1155/ancp/9411137.